CreditAccess Grameen Q3 FY26 results: PAT Rs 252 cr, ESOP grant of 9.12 lakh options

Results View source PDF Explain this filing

CREDITACC · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+9.4%Reaction day

₹1248.00

prior close

₹1309.00

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-0.7%+10.1% vs market

Finance peers, median of 388sector · industry level-0.8%+10.2% vs sector

On the reaction day the stock moved 10.1 pts more than Nifty Smallcap 250 and 10.2 pts more than its Finance peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.8

10m

+2.4

15m

+3.5

30m

+4.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+9.4-0.7+10.1-0.8+10.2

Next day

+15.4+0.2+15.2+0.1+15.3

+10.9-1.8+12.7-0.6+11.5

+6.7-1.6+8.3-1.0+7.7

+4.1+0.3+3.8-0.5+4.6

+1.8+0.2+1.6-0.9+2.7

+0.4-0.6+1.0-2.0+2.5

15d

+1.6+4.2-2.6+0.9+0.7

+3.0+2.8+0.2-1.4+4.4

-9.1-8.7-0.3-12.7+3.6

+0.6+5.9-5.2-1.6+2.2

UpDownMarket · Nifty Smallcap 250Sector · Finance peers, median of 388Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

CreditAccess Grameen reported Q3 FY26 standalone PAT of Rs 252.09 cr versus a loss of Rs 99.52 cr in Q3 FY25, a strong turnaround. Revenue from operations was Rs 1,490 cr. For 9M FY26, PAT was Rs 438.09 cr versus Rs 484.19 cr. Net worth Rs 7,413 cr, debt-equity 2.79, CRAR 26.44%, gross Stage 3 at 4.04%. Board also approved grant of 9,12,500 stock options under ESOP 2011 at Rs 1344.97 exercise price.

Likely market impact

Q3 profit turnaround is positive, but 9M PAT dipped slightly. ESOP grant may cause mild dilution. Capital position remains strong with healthy CRAR.